Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification
Surgery plays significant role in treatment of neurogenic tumors, both for benign ganglioneuroma and for high risk neuroblastoma. The world literature has accumulated large experience in laparoscopic surgery for abdominal neuroblastoma. The presence of IDRF (image-defined risk factors) and tumor size (\>4-7 cm) are con
| Condition(s) | Neuroblastoma, Ganglioneuroma, Ganglioneuroblastoma |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Surgery plays significant role in treatment of neurogenic tumors, both for benign ganglioneuroma and for high risk neuroblastoma. The world literature has accumulated large experience in laparoscopic surgery for abdominal neuroblastoma. The presence of IDRF (image-defined risk factors) and tumor size (\>4-7 cm) are considered as common contraindications for minimally invasive surgery in neuroblastoma. However, the recent studies have shown that presence of IDRF is not an absolute contraindication for laparoscopic surgery. This open-label, nonrandomized, observational, phase III evaluates role and weight of different surgical risk factors (including IDRF, tumor size, tumor localization, tumor volume/patient height ratio, previous open surgical procedures, previous chemotherapy etc.) in the |
| Who can participate | Inclusion Criteria: 1. Patients with neurogenic tumors meeting the criteria of groups I-III: Group I * low or moderate risk group according to pilot difficulty scoring system (less than 5 points, see supplementary material); * no IDRF; Group II: * low or moderate risk group according to pilot difficulty scoring system (less than 5 points); * patients with any number of IDRFs and without central tumor location and/or tumor extension across the midline and/or tumor volume (cm3)/patient height (m) ratio = 28 or more. Group III: * 2 and more IDRF + central tumor location and/or tumor extension across the midline; * 2 and more IDRF + tumor volume (cm3)/patient height (m) ratio = 28 or more; * 2 and more IDRF + 2 and more other risk factors according to pilot difficulty scoring system; * 1 IDRF |
| Ages | 1 Day to 18 Years |
| Sex | All |
| Lead sponsor | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
| Locations | Moscow, Russia |
| Start date | 2023-10-19 |
| NCT ID | NCT06296732 |
| Official listing | https://clinicaltrials.gov/study/NCT06296732 |